Aclaris Therapeutics
ACRS
102 hedge funds and large institutions have $703M invested in Aclaris Therapeutics in 2017 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 39 increasing their positions, 33 reducing their positions, and 22 closing their positions.
18% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 33
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less capital invested
Capital invested by funds: $737M → $703M (-$33.3M)
9% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 22
2% less funds holding
Funds holding: 104 → 102 (-2)
13.9% less ownership
Funds ownership: 106.29% → 92.38% (-14%)
99% less call options, than puts
Call options by funds: $20K | Put options by funds: $1.49M
Top Buyers
| 1 |
D.E. Shaw & Co
New York
|
+$24.6M |
| 2 |
DM
Deerfield Management
New York
|
+$16M |
| 3 |
Franklin Resources
San Mateo,
California
|
+$13.8M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.5M |
| 5 |
BlackRock
New York
|
+$11.8M |
Top Sellers
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$36.4M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$29.5M |
| 3 |
PC
PointState Capital
New York
|
-$17.7M |
| 4 |
NC
Nexthera Capital
New York
|
-$10.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$8.78M |
ACRS Hedge Fund Activity: Q4 2017 in Review
102 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q4 2017, worth a combined $703M — down 4.5% from $737M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ACRS and 20 opened new positions — a net loss of 2 holders — while 33 trimmed existing stakes and 39 added.
The largest buyer was D.E. Shaw & Co, adding an estimated $24.6M. The largest seller was Eagle Asset Management, exiting entirely with an estimated $36.4M sold.
- 102 institutional investors held Aclaris Therapeutics (ACRS) as of Q4 2017, down from 104 in Q3 2017.
- Funds reported $703M of Aclaris Therapeutics stock for Q4 2017, down 4.5% quarter-over-quarter.
- 20 funds opened new Aclaris Therapeutics positions in Q4 2017 and 22 closed out, a net change of -2 holders.
- The largest Aclaris Therapeutics buyer in Q4 2017 was D.E. Shaw & Co, an estimated $24.6M added.
- The largest Aclaris Therapeutics seller in Q4 2017 was Eagle Asset Management, an estimated $36.4M sold.
Based on aggregated 13F filings for Q4 2017.